Syndax Pharmaceuticals Inc. (NASDAQ:SNDX)’s share price rose 8.5% during trading on Tuesday . The company traded as high as $11.55 and last traded at $11.49, with a volume of 55,074 shares traded. The stock had previously closed at $10.59.

SNDX has been the topic of a number of analyst reports. Morgan Stanley lifted their target price on shares of Syndax Pharmaceuticals from $22.00 to $24.00 in a research report on Friday, April 8th. Oppenheimer Holdings Inc. reiterated a “buy” rating and issued a $24.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, May 17th. Citigroup Inc. assumed coverage on shares of Syndax Pharmaceuticals in a report on Monday, March 28th. They issued a “buy” rating and a $24.00 price target on the stock. Zacks Investment Research raised shares of Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 5th. Finally, JMP Securities assumed coverage on shares of Syndax Pharmaceuticals in a report on Monday, March 28th. They issued an “outperform” rating and a $28.00 price target on the stock. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $25.00.

The stock has a 50 day moving average price of $12.19 and a 200 day moving average price of $13.21. The stock’s market cap is $202.71 million.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its earnings results on Monday, May 16th. The company reported ($2.85) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.48) by $2.37. On average, equities research analysts expect that Syndax Pharmaceuticals Inc. will post ($2.93) earnings per share for the current year.

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications. Syndax is developing entinostat with a focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.